Evaluation of Metabolic Changes in FDG PET/CT Imaging After mRNA-based COVID-19 Vaccination
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Vaccine Reaction
- Sponsor
- Kocaeli University
- Enrollment
- 129
- Locations
- 1
- Primary Endpoint
- to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
It is important to evaluate the vaccine-related metabolic changes on FDG PET/CT to avoid confusing results. The investigators aimed to assess the frequency and intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine (BNT162b2-Pfizer/BioNTech) and to analyze possible factors affecting these changes.
Investigators
Serkan Isgoren
associate professor of nuclear medicine
Kocaeli University
Eligibility Criteria
Inclusion Criteria
- •patients referred for post-vaccination FDG PET/CT imaging
Exclusion Criteria
- •Disseminated metastatic disease, ipsilateral breast cancer or lymphoma that was likely to involve axilla, and patients who had ipsilateral intense axillary uptake or thyroiditis on their prior imaging, were exclusion criteria
Outcomes
Primary Outcomes
to assess the frequency of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine
Time Frame: 5 month
Frequency of metabolic changes
to assess the FDG intensity of regional and systemic metabolic PET/CT changes of patients who received the mRNA-based COVID-19 vaccine
Time Frame: 5 month
FDG intensity of metabolic changes